Uses of Xeroflam 1% Gel
Xeroflam 1% Gel is used for the treatment or prevention of the following disease(s):
Pain, Rheumatoid Arthritis
Side effects of Xeroflam 1% Gel
The most common side effects of Xeroflam 1% Gel are - Peeling, Swelling, Dryness, Irritation, Rash, Redness, Itching, Nausea, Acne
These side effects can usually occur in patients. However, these are only indicative and not all patients will experience them.
Precautions while taking Xeroflam 1% Gel
Do not use Xeroflam 1% Gel if you are allergic to - Diclofenac Topical
If you have heart disease, liver or kidney disease, drug or alcohol addiction, consult your doctor before using Xeroflam 1% Gel.
If you are allergic to any medicine or food, consult your doctor before using this medicine.
Use this medicine under the supervision of your doctor.
To avoid an adverse reaction, consult your doctor if you are already taking other medicines.
Dosage of Xeroflam 1% Gel
Xeroflam 1% Gel contains - Diclofenac Topical
Diclofenac works by blocking the effect called Cyclo-Oxygenase Enzymes. It help to make prostaglandins, which produced at sites of injury or damage, and cause pain and inflammation.
Overdose of Xeroflam 1% Gel
The dosage of Xeroflam 1% Gel depends on many factors such as the patient age, health, medical condition or history of the patient and many other conditions.
Please use this medicine as prescribed by your doctor.
Onset of Action of Xeroflam 1% Gel
If you forget to take a dose of Xeroflam 1% Gel, do not take two doses at the same time, there is a risk of overdose.
If you notice any unusual reaction in your body after taking this medicine, contact your doctor immediately or call your local medical emergency number.
Duration of Action of Xeroflam 1% Gel
Precautions & Warnings
Alcohol
Information will be added soon.
Pregnancy
Information will be added soon.
Breastfeeding
Information will be added soon.
Driving
Information will be added soon.
Kidney
Information will be added soon.
Liver
Information will be added soon.
Interactions
Information will be added soon.